anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses bepiastine. A formula consists of the following components by weight: 666g of bear gall powder and 3,200g of mile swertia, wherein a mile swertia raw material is required to be taken from a nationally-specified place, i.e., Mile in Yunnan Province; and the content of bear gall powder is required to reach a national medicament standard. A preparation method comprises the following steps of: extracting mile swertia twice by taking water as a solvent at the temperature of 80-90 DEG C, every time for 4 hours; combining extracting solutions; filtering with a micro water filter membrane; concentrating a filtrate in vacuum at a low temperature into thick paste of 1.30-1.35 (50 DEG C); drying into dry extract under reduced pressure; smashing the bear gall powder, mile swertia and dry extract respectively; sieving with a 120-mesh sieve, mixing uniformly and sterilizing; pilling with diluted ethanol, drying and preparing to 1,000g; and inspecting, performing split charging and warehousing. The formula of the bepiastine is scientific and reasonable, the requirements of mile swertia and bear gall powder raw materials are strict, a bepiastine product has stable quality and a perfect production process, and production conditions are consistent with Good Manufacturing Practice (GMP), i.e., a medicament production GMP standard. The bepiastine product has remarkable curative effects on the treatment of acute and chronic hepatitis, cholecystitis and gall-stone, resisting of arrhythmia, reduction in cholesterol in blood and triglyceride and prevention of hyperlipoidemia and renal hypertension. After long-term use, the bepiastine is free from untoward effects, and is safe and reliable.
Idiopathic pulmonary fibrosis (IPF) associated to pulmonary hypertension (PH) portends a poor prognosis, characterized by lung parenchyma fibrosis and pulmonary artery remodeling. Serum and parenchyma levels of Interleukin 11 (IL-11) are elevated in IPF-PH patients and contributes to pulmonary artery remodeling and PH. However, the effect of current approved therapies against IPF in pulmonary artery remodeling induced by IL-11 is unknown. The aim of this study is to analyze the effects of nintedanib and pirfenidone on pulmonary artery endothelial and smooth muscle cell remodeling induced by IL-11 in vitro. Our results show that nintedanib (NTD) and pirfenidone (PFD) ameliorates endothelial to mesenchymal transition (EnMT), pulmonary artery smooth muscle cell to myofibroblast-like transformation and pulmonary remodeling in precision lung cut slices. This study provided also evidence of the inhibitory effect of PFD and NTD on IL-11-induced endothelial and muscle cells proliferation and senescence. The inhibitory effect of these drugs on monocyte arrest and angiogenesis was also studied. Finally, we observed that IL-11 induced canonical signal transducer and activator of transcription 3 (STAT3) and non-canonical mitogen-activated protein kinase 1/2 (ERK1/2) phosphorylation, but, PFD and NTD only inhibited ERK1/2 phosphorylation. Therefore, this study provided evidence of the inhibitory effect of NTD and PFD on markers of pulmonary artery remodeling induced by IL-11.
This letter to the editor critiques a recent study evaluating the role of biologically effective dose (BED) in stereotactic radiosurgical thalamotomy for essential tremor (ET). The study, conducted retrospectively on 78 ET patients, demonstrates a significant correlation between BED and tremor improvement post-SRS. Moreover, the study suggests adjusting the prescribed dose rather than changing cobalt-60 sources to maintain treatment efficacy while minimizing toxicity. This suggestion aligns with previous research indicating an annual decrease in BED due to cobalt-60 decay. The letter emphasizes the importance of considering BED and cobalt-60 decay in optimizing treatment outcomes for ET patients undergoing stereotactic radiosurgery. Further research is recommended to explore innovative techniques for dose modulation in response to cobalt-60 decay and validate findings in larger cohorts.
Administration Information

Instruct patients to swallow Bupropion Hydrochloride Extended-release (SR) tablets whole so that the release rate is not altered. Do not chew, divide, or crush tablets; they are designed to slowly release drug in the body. When patients take more than 150 mg/day, instruct them to take Bupropion Hydrochloride Extended-release (SR) tablets in 2 doses at least 8 hours apart, to minimize the risk of seizures. Instruct patients if they miss a dose, not to take an extra tablet to make up for the missed dose and to take the next tablet at the regular time because of the dose-related risk of seizure. Instruct patients that Bupropion Hydrochloride Extended-release (SR) tablets may have an odor. Bupropion Hydrochloride Extended-release (SR) tablets can be taken with or without food.
INTRODUCTION: Ehlers-Danlos syndrome (EDS) and Joint Hypermobility syndrome (JHS) are still poorly understood, with a prevalence of 1/5000 for EDS and 1/500 for JHS. They are characterized by multisystem involvement. Urological involvement has been little studied. The aim was to carry out a review of the literature on the urological involvement of EDS and JHS.
METHOD: A review of the literature was carried out using the following databases: Pubmed, Canadian Hospitals and EMBASE. Search terms were "Ehlers-Danlos" or "Joint Hypermobility" associated with "Urology", "Bladder", "Pelvic Organ Prolapse", "Urinary Retention", "Leak", "Leakage", "Urinary Incontinence", "Urinary Tract Infection" and "Urdodynamic", no filters were added.
RESULTS: Seventy-three articles were included for a total of 259 found. The prevalence of urinary incontinence in EDS is estimated at 50-60%, and that of pelvic organ prolapse (POP) at 29-75%. Bladder diverticula are also frequently reported. For JHS, the prevalence of urinary incontinence is estimated between 40 and 73%, that of POP increased with 73% of stage greater than 2, g-JHS patients are almost 3 times more affected by prolapses (OR=2.37) which seem more severe. Patients with vesicoureteral reflux, most often severe, are more affected by joint hypermobility (OR=2.79). Few studies have been carried out on urological assessment and treatment modalities.
CONCLUSION: EDS patients often have urinary incontinence, pelvic organ prolapse or bladder diverticula. JHS patients frequently have urinary incontinence, pelvic organ prolapse and vesicoureteral reflux.
BACKGROUND: This study presents the pattern of respiratory effects seen among residents chronically exposed to gas flaring in some communities in the Niger Delta Region, Nigeria. The other health challenges associated with this chronic exposure to gas were also evaluated in the study.
METHODS: A total of three hundred and eighty-six 386 adult residents in Ibeno, Niger Delta Region who have been residents for at least two years. Four hundred and fourteen (414) age, sex, and height-matched control unexposed residents in Etinan were recruited for a cross-sectional survey study comparing their respiratory symptoms and other related health challenges. Past and current smokers were excluded from the study in both groups. The study was conducted using a questionnaire as the investigative tool. Both descriptive and inferential statistics were used to analyze the data.
RESULTS: Most of the respondents in both exposed and control communities were aged 18-30 years, with a height range of 161-170 cm. Both exposed and control subjects experienced similar symptoms suggestive of respiratory disorders, however, the prevalence was significantly higher among exposed subjects than controls: Cough 57(14.8%) vs. 39(10.1%); breathlessness 58(15%) vs. 28(7.3); wheezing 22(5.7) vs. 12(3.1). The respondents from the exposed community were mostly traders and fishermen while the controls were predominantly farmers.
CONCLUSION: There is substantial evidence from the data presented that prolonged exposure to air pollution from gas flaring has significant respiratory and other health implications on residents in these communities reflected as increased frequency of symptoms of cough, chest pain, difficulty in breathing, wheezing, chest tightness, Skin and eye irritation. There is therefore an urgent need for intensified efforts and commitment by the government to speed up the implementation of policies regarding the reduction of flaring of natural gas associated with oil production and the adoption of measures to mitigate the effect of the exposure on human health.
The deposition of immune complexes, activation of complement and infiltration of the kidney by cells of the adaptive and innate immune systems have long been considered responsible for the induction of kidney damage in autoimmune, alloimmune and other inflammatory kidney diseases. However, emerging findings have highlighted the contribution of resident immune cells and of immune molecules expressed by kidney-resident parenchymal cells to disease processes. Several types of kidney parenchymal cells seem to express a variety of immune molecules with a distinct topographic distribution, which may reflect the exposure of these cells to different pathogenic threats or microenvironments. A growing body of literature suggests that these cells can stimulate the infiltration of immune cells that provide protection against infections or contribute to inflammation - a process that is also regulated by draining kidney lymph nodes. Moreover, components of the immune system, such as autoantibodies, cytokines and immune cells, can influence the metabolic profile of kidney parenchymal cells in the kidney, highlighting the importance of crosstalk in pathogenic processes. The development of targeted nanomedicine approaches that modulate the immune response or control inflammation and damage directly within the kidney has the potential to eliminate the need for systemically acting drugs.
The invention relates to a medicine for treating high blood pressure. The medicine mainly takes Chinese herbal medicines such as Salvia miltiorrhiza Bunge, red paeony root, Ligusticum wallichii, licorice root, white paeony root, Achyranthes bidentata, Angelica sinensis, Astragalus membranaceus and the like as raw materials. The raw materials are repetitively stewed through mild fire. The obtained liquid medicine is concentrated into thick paste. Regular auxiliary materials are added into the thick paste to prepare clinically acceptable tablets, capsules, pills, particles, powders, injections or paste. The medicine of the invention can benefit qi and blood, tonify heart and dredge channels, clear heat and cool blood, and promote blood circulation and remove blood stasis, the medicine can be used to treat all kinds of high blood pressure, the treatment effect is good, the treatment cost is low and the like.
This study will recruit 3000 young adult sexual minority women (SMW), ages 18-30 years, current smokers (n = 1500) and not current smokers (n = 1500). The study will determine the effects of varying the dose (single vs. multiple), and latency (immediate vs. delayed) of showing participants inoculation anti-smoking messages on smoking and quitting intentions. The study team hypothesize that the multiple exposures (vs. single), and delayed exposure (vs. immediate) will be associated with increased resistance to marketing, reduced smoking intention, and increased quitting intention. The study team will further explore the mechanisms of inoculation effects through emotions, beliefs, and attitudes towards tobacco companies. Participants will be asked to complete a baseline survey and then will receive an anti-smoking message in varying dosages based on the condition they are assigned with a control group receiving no message. Participants will then see a pro-smoking or threat message immediately, one week, or one month late, depending on the condition they were assigned.
The aim of this study was to develop a long-acting transdermal patch of levamlodipine (LAM) using an ion-pair strategy to reduce the skin irritation induced by topical application of LAM and explore the mechanism underlying the improvement of skin irritation. The formulation was optimized through porcine in vitro transdermal experiments and rabbit in vivo skin irritation tests. The obtained formulation consisted of poly (2-Ethylhexyl acrylate-co-N-Vinyl-2-pyrrolidone-co-N-(2-Hydroxyethyl) acrylamide) (PENH) as the adhesive matrix, 13.00 % levamlodipine-sorbic acid ion-pair complex (LAM-SA) (w/w), and 10 % isopropyl myristate (IPM) (w/w), with a patch thickness of 70 μm, achieving an erythema index of 188 for rabbit skin and 117-187 for human skin (264 for rabbit skin and 110-260 for human skin in the absence of sorbic acid (SA)). In vivo rabbit and human skin erythema analysis and H&E staining verified that the optimized ion-pair patch effectively reduced skin irritation. Drug distribution experiments in the skin, ATR-FTIR, and molecular simulation were used to characterize the mechanism by which the ion-pair reduced skin irritation. Excessive accumulation of LAM in the epidermis induced secondary structural changes in keratin, resulting in skin barrier damage and inflammatory response. The formation of the LAM-SA ion pair altered physicochemical properties of LAM, reducing drug retention in the epidermis and, thereby, reducing skin irritation. This study demonstrated the potential of the ion-pair strategy to improve the safety of transdermal drug delivery system (TDDS) and provided a means for reducing skin irritation caused by the active pharmaceutical ingredient (API) itself.
<P>PROBLEM TO BE SOLVED: To provide materials and methods for treating disease states (including cancer and autoimmune disease) by facilitating or inhibiting the migration or activation of antigen-presenting dendritic cells, since dendritic cells play a critical role in antigen-specific immune responses.  <P>SOLUTION: Materials and methods for treating disease states (including cancer and autoimmune disease) are provided by facilitating or inhibiting the migration or activation of antigen-presenting dendritic cells, since dendritic cells play a critical role in antigen-specific immune responses. In particular, chemokines are used to initiate, amplify or modulate an immune response. In one embodiment, chemokines are used to attract dendritic cells to the site of antigen delivery. An increased number of dendritic cells at the site of antigen delivery means more antigen uptake and a modified immune response.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The study will be a randomized clinical trial conducted at the Pakistan Sports Board and The Raider's football club over a duration of 10 months after synopsis approval. The required sample size for each group, after accounting for a 10% attrition rate, will be 37. Two study groups will be established: Group A, which will receive calcaneal taping among football players, and Group B, which will receive windlass taping among football players. Nonprobability purposive sampling will be employed. Data will be collected using the Numeric Pain Rating Scale (NPRS), Hubscher maneuver, goniometer, and lower extremity functional scale (LEFS) to assess pain severity, flat foot type flexibility, joint range of motion, and lower limb function, respectively. This comprehensive study aims to contribute valuable insights into the effects of calcaneal and windlass taping on football players.
The usual dosage employed varies with the site and method of injection and the age, condition and weight of the patient. In adults, carotid and vertebral angiography, by either the percutaneous needle or catheter methods, is usually performed with a single rapid injection of 6 to 10 mL. Additional injections are made as indicated. Retrograde brachial cerebral angiography, in adults, is usually performed with a single rapid injection of 35 to 50 mL into the right brachial artery. Other dosages may be employed depending upon the vessel injected and the procedure followed. The dose for children is reduced in approximate proportion to age and body weight.
Subjects involved in the study will be evaluated with various non-invasive assessments including the Richmond Agitation-Sedation Scale, pain assessments on a Numeric Rating Scale (NRS-11), and CAM-ICU scale. Blood draws will also take place in order to perform microRNA testing in all subjects participating in the trial. Standardized anesthetic care as described by the approved protocol will be followed for each subject included in this trial.
Participants in the control arm will receive a 5-day course of placebo tablets in addition to standard of care. The participants will receive 3 tablets twice daily for 5 days. The placebo tablets have the same shape and appearance as the active comparator product. The tablets containing placebo and active comparato have both been encapsulated in the same way to maintain blinding.
OBJECTIVE: The purpose of this study is to use two-sample Mendelian randomization (MR) to investigate the causal relationship between skin microbiota, especially Propionibacterium acnes, and intervertebral disc degeneration (IVDD), low back pain (LBP) and sciatica.
METHODS: We conducted a two-sample MR using the aggregated data from the whole genome-wide association studies (GWAS). 150 skin microbiota were derived from the GWAS catalog and IVDD, LBP and sciatica were obtained from the IEU Open GWAS project. Inverse-variance weighted (IVW) was the primary research method, with MR-Egger and Weighted median as supplementary methods. Perform sensitivity analysis and reverse MR analysis on all MR results and use multivariate MR to adjust for confounding factors.
RESULTS: MR revealed five skin microbiota associated with IVDD, four associated with LBP, and two with sciatica. Specifically, P.acnes in sebaceous skin environments were associated with reduced risk of IVDD; IVDD was found to increase the abundance of P.acnes in moist skin. Furthermore, ASV010 [Staphylococcus (unc.)] from dry skin was a risk factor for LBP and sciatica; ASV045 [Acinetobacter (unc.)] from dry skin and Genus Rothia from dry skin exhibited potential protective effects against LBP; ASV065 [Finegoldia (unc.)] from dry skin was a protective factor for IVDD and LBP. ASV054 [Enhydrobacter (unc.)] from moist skin, Genus Bacteroides from dry skin and Genus Kocuria from dry skin were identified as being associated with an increased risk of IVDD. Genus Streptococcus from moist skin was considered to be associated with an increased risk of sciatica.
CONCLUSIONS: This study identified a potential causal relationship between skin microbiota and IVDD, LBP, and sciatica. No evidence suggests skin-derived P.acnes is a risk factor for IVDD, LBP and sciatica. At the same time, IVDD can potentially cause an increase in P.acnes abundance, which supports the contamination theory.
PURPOSE: Provided is a fungicide composition containing extracts derived from plants which include Foeniculum vulgare, Illicium verum Hook. fil., Asarum Sieboldii Miquel var. seoulens Nakai., Lindera erythrocarpa Makino., etc., and inhibit the growth of pathogenic fungi. CONSTITUTION: A fungicide composition characteristically comprises, as active ingredients, fenchone, eugenol, isoeugenol, methyleugenol, cinnamic alcohol, and cinnamic aldehyde which are extracted from Foeniculum vulgare, Illicium verum Hook. fil., Asarum Sieboldii Miquel var. seoulens Nakai., Lindera erythrocarpa Makino., and Eugenia caryophyllata. It has antifungal effects on Trichophyton and candida species.
Participants receive up to two interventions. Participants receive HE initially and then I2 if not screened after 6 months.
Patients on hemodialysis patients present anatomic and functional abnormalities on peripheral bed vases and also cardiovascular abnormalities that can cause myocardial ischemia. This last usually is transitory and lead to left ventricular dysfunction that can persist even after the end of dialysis session despite normal coronary perfusion. The prolonged dysfunction is called myocardial stunning (MS). Patients on dialysis are subject to hemodynamic instability, myocardial ischemia and development of regional abnormalities of myocardial wall (ARPM´s). Some authors have demonstrated that CHD cause segmental and global myocardial ischemia, and up to 65% of patients have recurrent myocardial ischemia. There are some associated factors: high ultrafiltration rates, intradialytic hypotension, reduced systolic blood pressure and high risk of cardiovascular events and death. MS induced by intradialytic ischemia is a complication that can be minimized by applying techniques associated to more stability during the CHD, as cool dialysate or increasing the length of the therapy. More specifically, MS can be the result of repair process, with oxygen free radicals generation and reduction of the synthesis of contractile proteins, in association with a reduced muscle responses to calcium which in turns lead to ventricular dysfunction (the calcium hypothesis). The goal of the present study is to evaluate the behavior of cardiovascular system (trough hemodynamic performance during CHD, accessing MS by echocardiography technique, and biomarkers associated to MS). Finally, the investigators aimed to investigate the role of two different dialysate calcium concentration (2,5 and 3,5 mEq/l) in the genesis of MS during CHD. The elucidation of pathogenesis of MS during CHD might help us modified hemodialysis technique in order to prevent MS, and reduce the high cardiovascular mortality among CKD patients.
Osteoporosis is the most common type of bone disease. Calcium supplements normally used in anti-osteoporosis treatment are calcium salts of carbonate or citrate; however, these salts bind phosphorus from food in the intestine and restrict phosphorus available for bone building. This study will evaluate the efficacy of adding calcium phosphate to a regimen of teriparatide and vitamin D in increasing bone mineral density in women with osteoporosis. It is hypothesized that the group taking the phosphate-containing calcium supplement will have greater gains in bone mineral density (BMD) during the course of the study than the group not receiving phosphate.

All participants will receive teriparatide and vitamin D during the course of the 12-month study. Participants will be randomly assigned to one of two groups. One group will receive calcium phosphate and the other will receive calcium carbonate. BMD will be measured at spine and hip at baseline and at 3, 6, and 12 months of treatment.
Part C will be an open-label, randomised, 2-period crossover relative bioavailability study of MBS2320 in capsules or suspension. The intention is to enrol 8 healthy subjects. Each subject will participate in 2 treatment periods.